In patients with acute HF and iron deficiency, IV ferric carboxymaltose improved quality of life at 4 to 24 wk

Ann Intern Med. 2021 Oct;174(10):JC110. doi: 10.7326/ACPJ202110190-110. Epub 2021 Oct 5.

Abstract

Jankowska EA, Kirwan BA, Kosiborod M, et al. The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. Eur Heart J. 2021;42:3011-20. 34080008.

Publication types

  • Comment

MeSH terms

  • Anemia, Iron-Deficiency* / drug therapy
  • Ferric Compounds
  • Heart Failure*
  • Humans
  • Maltose / analogs & derivatives
  • Quality of Life

Substances

  • Ferric Compounds
  • ferric carboxymaltose
  • Maltose